Edition:
United States

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

103.20EUR
11:35am EDT
Change (% chg)

€-0.65 (-0.63%)
Prev Close
€103.85
Open
€103.15
Day's High
€103.50
Day's Low
€102.10
Volume
396,944
Avg. Vol
417,325
52-wk High
€105.55
52-wk Low
€71.15

Latest Key Developments (Source: Significant Developments)

FDA approves treatment for metastatic merkel cell carcinoma
Thursday, 23 Mar 2017 02:28pm EDT 

U.S. FDA: Granted accelerated approval to Bavencio for treatment of adults, pediatric patients 12 years and older with metastatic merkel cell carcinoma .Further clinical trials are required to confirm Bavencio’s clinical benefit.  Full Article

Merck KGaA announces release of two fertility technologies products
Friday, 10 Mar 2017 05:13am EST 

Merck Kgaa :release of 2 fertility technologies products for improved efficiency in assisted reproductive treatment lab, eevatest 3.0, geri humidified incubation.  Full Article

Beigene says expects decision in Q1 of 2017 from partner Merck KGaA on BGB-283
Thursday, 2 Mar 2017 09:00am EST 

Beigene Ltd :Beigene says expects decision in Q1 of 2017 from partner Merck KGaA on continuation option to develop, commercialize BGB-283 outside China.  Full Article

Merck says NICE expands a positive recommendation for Erbitux
Thursday, 2 Mar 2017 02:04am EST 

Merck KGaA :Says NICE expands positive recommendation for Erbitux as first-line treatment for RAS Wild-type mCRC.  Full Article

Pfizer sees 2017 Prevnar sales flat to slightly down
Tuesday, 31 Jan 2017 11:42am EST 

Pfizer Inc : Pfizer CEO says M&A focus on opportunities that contribute immediate or near-term revenue growth . Pfizer sees avelumab as core asset in immuno-oncology franchise with 30 ongoing trials . Pfizer CEO says looks forward to working with new Trump administration in 2017 . Pfizer sees 2017 Prevnar sales flat to slightly down .Pfizer CEO says not changing philosophy on drug pricing or when company takes increases.  Full Article

Merck Kgaa, Darmstadt, Germany, Palantir launch new healthcare partnership
Thursday, 12 Jan 2017 05:00pm EST 

Merck Kgaa : Merck KGAA - Merck KGAA, Darmstadt, Germany, and Palantir launch new healthcare acceleration partnership . Merck KGAA - financial details were not disclosed . Merck KGAA - initially Merck KGAA, Darmstadt, Germany, will apply Palantir's technology to cancer treatment and patient services .Merck KGAA - ultimately Merck KGAA, Darmstadt, Germany, plans to deploy Palantir's technology across all three of company's business sectors.  Full Article

Merck and CLEARink Displays sign development agreement
Tuesday, 10 Jan 2017 04:20am EST 

Merck Kgaa :Signs a comprehensive materials development agreement with CLEARink Displays, Inc., aiming to bring CLEARink's innovative and patented reflective display technology to market by end of 2017.  Full Article

Advanced Nano Technologies signs revised supply agreement with Merck KGaA
Thursday, 22 Dec 2016 12:53am EST 

Advanced Nano Technologies Ltd : expects as a result of agreement that it will positively impact on profitability of co in fy17 & fy18 . Terms of revised agreement remain confidential .Reached agreement with merck kgaa to revise terms of its existing supply arrangements for alusion.  Full Article

Roche expands distribution alliance with life science business
Thursday, 1 Dec 2016 08:00am EST 

Merck Kgaa :Roche expands distribution alliance with life science business of Merck kgaa, darmstadt, Germany to include kapa biosystems qpcr and endpoint pcr portfolios.  Full Article

Transgene announces collaboration with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate the combination of TG4001 with Avelumab
Tuesday, 11 Oct 2016 11:47am EDT 

Transgene : Transgene announces collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate the combination of TG4001 with Avelumab in HPV-positive head & neck cancer in a phase 1/2 study . Transgene- this is an exclusive agreement between parties to study combination of these two classes of investigational agents in HPV-positive HNSCC .Transgene- phase I trial is expected to begin in France, with first patient expected to be recruited in H1 2017.  Full Article

More From Around the Web

FDA approves Pfizer, German Merck immunotherapy for skin cancer

U.S. health regulators on Thursday approved a drug developed by Merck KGaA and Pfizer Inc that helps the immune system to fight a rare form of skin cancer once it has spread to other parts of the body.